Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diabetes-suppressive dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- DiaVacs
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
The diabetes-suppressive dendritic cell vaccine is an autologous cell-based immunotherapy designed to treat type 1 diabetes mellitus (T1DM). It consists of a patient's own monocyte-derived dendritic cells that are modified ex vivo with a mixture of phosphorothioate-modified antisense oligonucleotides targeting the primary transcripts of the co-stimulatory molecules CD40, CD80, and CD86. This silencing process renders the dendritic cells tolerogenic (immunosuppressive), meaning they can suppress the autoimmune response against pancreatic beta cells rather than stimulating it. Developed at the University of Pittsburgh and licensed to DiaVacs, Inc., the vaccine is administered intradermally at sites near the pancreas to induce immune tolerance and potentially preserve residual beta-cell function in patients with established or new-onset T1DM.
- Other names
- diabetes-suppressive dendritic cellsautologous monocyte-derived dendritic cells treated with antisense oligonucleotidestolerogenic dendritic cell vaccine
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)
Beyond the preview
Go deeper on diabetes-suppressive dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diabetes-suppressive dendritic cell vaccine.